Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923655 | 0.93 | PKM (0.46) | PKMLMNACRHR1 | |
| SCHEMBL31651623 | 0.77 | DRD2 (0.35) | LMNA | |
| SCHEMBL38654031 | 0.76 | PDE10A (0.36) | PKMCRHR1 | |
| Hydrochloric Acid SCHEMBL31652076 | 0.75 | DRD2 (0.34) | — | |
| SCHEMBL8105760 | 0.72 | HDAC9 (0.33) | — | |
| SCHEMBL38653385 | 0.72 | PDE10A (0.37) | — | |
| SCHEMBL17213862 | 0.70 | — | — | |
| SCHEMBL16058867 | 0.69 | ALOX15 (0.34) | PKM | |
| Hydrochloric Acid SCHEMBL18493636 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL17499076 | 0.68 | ALOX15 (0.33) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243385-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2677869-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2017-11-08 | — | — | EP | disclosed |
| US-8796258-B2 | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| CN-103476258-A | Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents | MERCK SHARP & DOHME | 2013-12-25 | — | — | CN | disclosed |
| US-20130123237-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123237-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAB2, PRKAG1 | PKM 1188/4885LMNA 3606/4885CRHR1 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.